- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: BI 10773 | Jardiance®
empagliflozin is an approved drug (FDA & EMA (2014))
Compound class: Natural product or derivative
Comment: Empagliflozin is a member of the 'gliflozin' class of drugs which inhibit reabsorption of glucose in the kidney to lower blood sugar.
It is the first glucose-lowering, antidiabetes therapy to be granted approval to reduce the risk of cardiovascular (CV) death in type 2 diabetes patients with CV disease.
SARS-CoV-2 and COVID-19: Empagliflozin was added to the RECOVERY trial (NCT04381936) in July 2021, to determine if using empagliflozin to correct metabolic dysregulation caused by SARS-CoV-2 infection can protect against organ damage and improve recovery in COVID-19 patients. This was predicated by results of a study exploring dapagliflozin-mediated organ protection, which found that the drug elicited a non-significant reduction in the risk of organ failure or death in COVID-19 patients .
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
View more information in the IUPHAR Pharmacology Education Project: empagliflozin
|Compound class||Natural product or derivative|
|Approved drug?||Yes (FDA & EMA (2014))|
|WHO Essential Medicine||WHO Essential Medicines List (EML) (22nd List, 2021). Access PDF version.
Click to view more information about the WHO Model Lists of Essential Medicines.
|International Nonproprietary Names|
|BI 10773 | Jardiance®|
|CAS Registry No.||864070-44-0 (source: Scifinder)|
|GtoPdb PubChem SID||178101464|
|RCSB PDB Ligand||7R3|
|Search Google for chemical match using the InChIKey||OBWASQILIWPZMG-QZMOQZSNSA-N|
|Search Google for chemicals with the same backbone||OBWASQILIWPZMG|
|Search PubMed clinical trials||empagliflozin|
|Search PubMed titles||empagliflozin|
|Search PubMed titles/abstracts||empagliflozin|
|Search UniChem for chemical match using the InChIKey||OBWASQILIWPZMG-QZMOQZSNSA-N|
|Search UniChem for chemicals with the same backbone||OBWASQILIWPZMG|